Quality of life in patients with active sarcoidosis in Greece

Αντωνίου, Κατερίνα; Tzanakis, Νikolaos; Τzouvelekis, Αrgyris; Samiou, Maria; Symvoulakis, Emmanouil K.; Siafakas, Nikolaos M.; Bouros, Demosthenes

doi:10.1016/j.ejim.2006.02.024

Cited by 22 publications

(21 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These findings are similar to those of Cox et al [42], who reported an even greater reduction in HrQoL. In contrast to our study, Gvozdenovic et al [43] and Antoniou et al [44] described HrQoL in a hospital setting. Moreover, they assessed patients who were less severely affected by sarcoidosis than those in our study, thus the results cannot be compared directly.…”

Section: Discussioncontrasting

confidence: 57%

Short-Term Effects of a Multimodal 3-Week Inpatient Pulmonary Rehabilitation Programme for Patients with Sarcoidosis: The ProKaSaRe Study

Lingner

Buhr-Schinner²,

Hummel

et al. 2018

Respiration

View full text Add to dashboard Cite

Background: Real-world data on the effects of a multicomponent pulmonary rehabilitation (PR) for patients with sarcoidosis are scarce. Objective: To describe characteristics of patients with sarcoidosis referred for a 3-week inpatient PR, to assess the effects of PR on their quality of life (QoL) and clinical outcomes, and to investigate whether there are specific subgroups who particularly benefit from PR. Methods: Using a prospective multicentre study design, data regarding 6-min walking distance (6MWD), QoL (Saint George’s Respiratory Questionnaire, SGRQ), and the secondary outcomes of dyspnoea and psychological burden (fatigue, anxiety, and depression) were collected. Results: We included 296 patients in the study (average age 49.1 ± 9.7 years, 47% female, average vital capacity 3.5 ± 1.0 L [87.0 ± 20.6 predicted]). The 6MWD improved by the end of the rehabilitation by 39.8 m on average (p < 0.0001; standardised response mean, SRM = 0.61), SGRQ showed significant improvements in all 3 domains, and the total score (p < 0.001) improved by 5.69–8.28 points (SRM 0.46–0.62). For the secondary outcomes, significant improvement (p < 0.001) was seen for all measured parameters, e.g., dyspnoea (modified Medical Research Council Scale, mMRC), fatigue (Fatigue Assessment Scale [FAS]; SRM = –0.71), anxiety and depression (Hospital Anxiety and Depression Scale [HADS]; SRM –0.58/–0.38), and generic QoL (measured by the SF-36 scales of physical and mental health; SRM 0.31/0.55). Conclusions: Our results provide the first documented evidence that PR is a promising complementary therapy option for sarcoidosis patients who remain subjectively symptomatic despite optimised outpatient medical treatment.

show abstract

Section: Discussioncontrasting

confidence: 57%

Short-Term Effects of a Multimodal 3-Week Inpatient Pulmonary Rehabilitation Programme for Patients with Sarcoidosis: The ProKaSaRe Study

Lingner

Buhr-Schinner²,

Hummel

et al. 2018

Respiration

View full text Add to dashboard Cite

show abstract

“…65 They include the Medical Outcome Study 36item Short Form Health Survey (SF-36) 30,[66][67][68][69][70][71][72][73][74][75] the World Health Organization Quality of Life Assessment Instrument-100 (WHOQOL-100), 31,34,[76][77][78][79][80] and the 26-item abbreviated WHOQOL instrument (WHOQOL-BREF). 45,79,[81][82][83] The pulmonary specific St. George's Respiratory Questionnaire (SGRQ), 30,32,73,[84][85][86][87][88][89][90] as well as several commonly used ocular and skin-specific generic HRQoL assessment measures have also been included in this group (►Table 2).…”

Section: Generic Hrqol Proms Used In Sarcoidosismentioning

confidence: 99%

“…30,32,73,[84][85][86][87][88][89][90]103 A cross-sectional study that included 75 patients with active sarcoidosis in Greece found that compared with healthy controls, patients with sarcoidosis have poorer HRQoL. 32 In that study, the SGRQ was significantly correlated with lung function tests (FEV1 and FVC), longer duration of disease, and dyspnea but not with chest radiography. 32 Other studies have shown that a reduced 6MWD 84 and dyspnea 86 are also associated with poorer HRQoL.…”

Section: The World Health Organization Quality Of Life Assessment Insmentioning

confidence: 99%

“…30 This is despite the fact that available data suggests that there is minimal to no correlation between spirometry and chest radiograph findings on patient perceived symptoms and HRQoL. [30][31][32] Indeed, it is plausible that a treatment goal aimed at improving physiologic and radiographic parameters without incorporating HRQoL assessments may be perceived poorly by the patient as causing "more harm than good" due to an excess of medication side effects over perceived and/or realized benefits. In a multicenter study evaluating patients treated at three U.S. academic institutions, patients treated with corticosteroids had significantly lower HRQoL scores than those who did not receive corticosteroids.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Health-Related Quality of Life in Sarcoidosis

Ndili

2020

Semin Respir Crit Care Med

View full text Add to dashboard Cite

Health-related quality of life (HRQoL) describes an individual's perception of the impact of health, disease, and treatment on their quality of life (QoL). It is a reflection of how the manifestation of an illness and its treatment is personally experienced. Assessing HRQoL is particularly important in sarcoidosis because the attributable disease mortality is relatively low, and one of the major reasons for initiating treatment is to improve quality of life. HRQoL has been assessed in sarcoidosis using various generic and sarcoid-specific patient-reported outcome measures (PROMs). It is important that both the direct and indirect effects of the disease, as well as potential toxicities of therapy, are captured in the various PROMs used to assess HRQoL in sarcoidosis. This article provides a general overview of HRQoL in patients with sarcoidosis. It describes the various PROMs used to assess HRQoL in sarcoidosis and addresses the various factors that influence HRQoL in sarcoidosis. Specific attention is paid to fatigue, small fiber neuropathy, corticosteroid therapy, and other disease-specific factors that affect HRQoL in sarcoidosis. It also provides an insight into interventions that have been associated with improved HRQoL in sarcoidosis and offers suggestions for future research in this important area.

show abstract

“…Among patients with sarcoidosis, a high incidence of alexithymic personality traits has also been evidenced [6–9]. …”

Section: Introductionmentioning

confidence: 99%

Sarcoidosis: Psychotherapy and Long-Term Outcome—A Case Report

Trombini

2012

Case Reports in Medicine

View full text Add to dashboard Cite

Sarcoidosis is a systemic, inflammatory disease of unknown aetiology, influenced by stressful life events and associated with a high incidence of alexithymic personality traits, and of depressive symptoms. The medical literature on sarcoidosis has called for a psychotherapeutic intervention to modify the perceived state of disease, the influence of stressful events and the depressive condition. Few studies have described cases treated with psychotherapy, and no information is available on its long-term outcome. We present the case of a patient with chronic sarcoidosis and periodical reacutizations with constantly pathological ESR. Twenty-four years after the diagnosis, a dynamic supportive-expressive psychotherapy for psychosomatic alexithymic patients was added to the medical therapy. At the beginning and at the end of the psychotherapy, and for the long-term outcome evaluations, Kellner's symptom questionnaire (SQ) was used to investigate psychological distress. The SQ scores, initially pathological, were normal at the end of the psychotherapy and for the following three years. Psychotherapy, without antidepressive drugs, resolved the depression. The depressive symptoms disappeared, along with the normalization and stabilization of the ESR. After three years, the outcome was positive. This is the first study describing a successful psychotherapy and its long-term outcome on a patient with sarcoidosis.

show abstract

Quality of life in patients with active sarcoidosis in Greece

Cited by 22 publications

References 28 publications

Short-Term Effects of a Multimodal 3-Week Inpatient Pulmonary Rehabilitation Programme for Patients with Sarcoidosis: The ProKaSaRe Study

Short-Term Effects of a Multimodal 3-Week Inpatient Pulmonary Rehabilitation Programme for Patients with Sarcoidosis: The ProKaSaRe Study

Health-Related Quality of Life in Sarcoidosis

Sarcoidosis: Psychotherapy and Long-Term Outcome—A Case Report

Contact Info

Product

Resources

About